Dr. Tanya C. Watt
Claim this profileUT Southwestern/Simmons Cancer Center-Dallas
Expert in Neuroblastoma
Studies Cancer
15 reported clinical trials
34 drugs studied
Area of expertise
1Neuroblastoma
Global LeaderMYC positive
Stage IV
MYC negative
2Cancer
Stage IV
Affiliated Hospitals
Clinical Trials Tanya C. Watt is currently running
DFMO + Etoposide
for Neuroblastoma
This trial uses two drugs, DFMO and etoposide, to treat children whose neuroblastoma has come back or didn't respond to initial treatments. DFMO stops cancer cells from growing, and etoposide helps kill them. The study includes patients who are recovering after additional therapy, those who have had the disease return but are currently without symptoms, and those with active disease. DFMO has been evaluated as a follow-up treatment for severe neuroblastoma in previous studies.
Recruiting1 award Phase 2
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
More about Tanya C. Watt
Clinical Trial Related4 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Tanya C. Watt has experience with
- Laboratory Biomarker Analysis
- Dinutuximab
- Cytology Specimen Collection Procedure
- Temozolomide
- Vorinostat
- Quality-of-Life Assessment
Breakdown of trials Tanya C. Watt has run
Neuroblastoma
Cancer
Ganglioneuroblastoma
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tanya C. Watt specialize in?
Tanya C. Watt focuses on Neuroblastoma and Cancer. In particular, much of their work with Neuroblastoma has involved MYC positive patients, or patients who are Stage IV.
Is Tanya C. Watt currently recruiting for clinical trials?
Yes, Tanya C. Watt is currently recruiting for 6 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Tanya C. Watt has studied deeply?
Yes, Tanya C. Watt has studied treatments such as Laboratory Biomarker Analysis, Dinutuximab, Cytology Specimen Collection Procedure.
What is the best way to schedule an appointment with Tanya C. Watt?
Apply for one of the trials that Tanya C. Watt is conducting.
What is the office address of Tanya C. Watt?
The office of Tanya C. Watt is located at: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas 75390 United States. This is the address for their practice at the UT Southwestern/Simmons Cancer Center-Dallas.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.